Cargando…

Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma

Multiple myeloma (MM) is a hematological malignancy that remains incurable because most patients eventually relapse or become refractory to current treatments. Although the treatments have improved, the major problem in MM is resistance to therapy. Clonal evolution of MM cells and bone marrow microe...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Wen-Chi, Lin, Sheng-Fung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4663284/
https://www.ncbi.nlm.nih.gov/pubmed/26649299
http://dx.doi.org/10.1155/2015/341430
_version_ 1782403268114120704
author Yang, Wen-Chi
Lin, Sheng-Fung
author_facet Yang, Wen-Chi
Lin, Sheng-Fung
author_sort Yang, Wen-Chi
collection PubMed
description Multiple myeloma (MM) is a hematological malignancy that remains incurable because most patients eventually relapse or become refractory to current treatments. Although the treatments have improved, the major problem in MM is resistance to therapy. Clonal evolution of MM cells and bone marrow microenvironment changes contribute to drug resistance. Some mechanisms affect both MM cells and microenvironment, including the up- and downregulation of microRNAs and programmed death factor 1 (PD-1)/PD-L1 interaction. Here, we review the pathogenesis of MM cells and bone marrow microenvironment and highlight possible drug resistance mechanisms. We also review a potential molecular targeting treatment and immunotherapy for patients with refractory or relapse MM.
format Online
Article
Text
id pubmed-4663284
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-46632842015-12-08 Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma Yang, Wen-Chi Lin, Sheng-Fung Biomed Res Int Review Article Multiple myeloma (MM) is a hematological malignancy that remains incurable because most patients eventually relapse or become refractory to current treatments. Although the treatments have improved, the major problem in MM is resistance to therapy. Clonal evolution of MM cells and bone marrow microenvironment changes contribute to drug resistance. Some mechanisms affect both MM cells and microenvironment, including the up- and downregulation of microRNAs and programmed death factor 1 (PD-1)/PD-L1 interaction. Here, we review the pathogenesis of MM cells and bone marrow microenvironment and highlight possible drug resistance mechanisms. We also review a potential molecular targeting treatment and immunotherapy for patients with refractory or relapse MM. Hindawi Publishing Corporation 2015 2015-11-16 /pmc/articles/PMC4663284/ /pubmed/26649299 http://dx.doi.org/10.1155/2015/341430 Text en Copyright © 2015 W.-C. Yang and S.-F. Lin. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Yang, Wen-Chi
Lin, Sheng-Fung
Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma
title Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma
title_full Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma
title_fullStr Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma
title_full_unstemmed Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma
title_short Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma
title_sort mechanisms of drug resistance in relapse and refractory multiple myeloma
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4663284/
https://www.ncbi.nlm.nih.gov/pubmed/26649299
http://dx.doi.org/10.1155/2015/341430
work_keys_str_mv AT yangwenchi mechanismsofdrugresistanceinrelapseandrefractorymultiplemyeloma
AT linshengfung mechanismsofdrugresistanceinrelapseandrefractorymultiplemyeloma